181 related articles for article (PubMed ID: 30343213)
1. TP53 mutation in allogeneic hematopoietic cell transplantation for de novo myelodysplastic syndrome.
Kim YJ; Jung SH; Hur EH; Choi EJ; Lee KH; Yim SH; Kim HJ; Kwon YR; Jeon YW; Lee SH; Chung YJ; Lee JH
Leuk Res; 2018 Nov; 74():97-104. PubMed ID: 30343213
[TBL] [Abstract][Full Text] [Related]
2. Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation.
Caballero JC; Sánchez Barba M; Hernández Sánchez JM; Such E; Janusz K; Sanz G; Cabrero M; Chillón C; Cervera J; Hurtado AM; Jerez A; Calderón Cabrera C; Valcárcel D; Lumbreras E; Abáigar M; López Cadenas F; Hernández Rivas JM; Del Cañizo MC; Díez Campelo M
Ann Hematol; 2019 Sep; 98(9):2151-2162. PubMed ID: 31312927
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
4. TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis.
Loghavi S; Al-Ibraheemi A; Zuo Z; Garcia-Manero G; Yabe M; Wang SA; Kantarjian HM; Yin CC; Miranda RN; Luthra R; Medeiros LJ; Bueso-Ramos CE; Khoury JD
Br J Haematol; 2015 Oct; 171(1):91-9. PubMed ID: 26123119
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.
Lindsley RC; Saber W; Mar BG; Redd R; Wang T; Haagenson MD; Grauman PV; Hu ZH; Spellman SR; Lee SJ; Verneris MR; Hsu K; Fleischhauer K; Cutler C; Antin JH; Neuberg D; Ebert BL
N Engl J Med; 2017 Feb; 376(6):536-547. PubMed ID: 28177873
[TBL] [Abstract][Full Text] [Related]
6. Impact of Epigenomic Hypermethylation at TP53 on Allogeneic Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndromes.
Wang W; Auer P; Zhang T; Spellman S; Carlson KS; Nazha A; Bolon YT; Saber W
Transplant Cell Ther; 2021 Aug; 27(8):659.e1-659.e6. PubMed ID: 33992829
[TBL] [Abstract][Full Text] [Related]
7. Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes.
Christopeit M; Badbaran A; Alawi M; Zabelina T; Zeck G; Wolschke C; Ayuk F; Kröger N
Eur J Haematol; 2016 Sep; 97(3):288-96. PubMed ID: 26680262
[TBL] [Abstract][Full Text] [Related]
8. Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60-69 years with myelodysplastic syndrome.
Itonaga H; Ishiyama K; Aoki K; Aoki J; Ishikawa T; Uchida N; Ohashi K; Ueda Y; Fukuda T; Sakura T; Ohno Y; Iwato K; Okumura H; Kondo T; Ichinohe T; Takanashi M; Atsuta Y; Miyazaki Y
Ann Hematol; 2019 Jun; 98(6):1367-1381. PubMed ID: 30854574
[TBL] [Abstract][Full Text] [Related]
9. Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study.
Sengsayadeth S; Gatwood KS; Boumendil A; Labopin M; Finke J; Ganser A; Stelljes M; Ehninger G; Beelen D; Niederwieser D; Blaise D; Dreger P; Mufti G; Chevallier P; Mailhol A; Gilleece MH; Gorin N; Esteve J; Ciceri F; Baron F; Schmid C; Giebel S; Mohty M; Savani BN; Nagler A
Blood Adv; 2018 Aug; 2(16):2127-2135. PubMed ID: 30143527
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study.
Versluis J; Saber W; Tsai HK; Gibson CJ; Dillon LW; Mishra A; McGuirk J; Maziarz RT; Westervelt P; Hegde P; Mukherjee D; Martens MJ; Logan B; Horowitz M; Hourigan CS; Nakamura R; Cutler C; Lindsley RC;
J Clin Oncol; 2023 Oct; 41(28):4497-4510. PubMed ID: 37607457
[TBL] [Abstract][Full Text] [Related]
11. Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation.
Heuser M; Gabdoulline R; Löffeld P; Dobbernack V; Kreimeyer H; Pankratz M; Flintrop M; Liebich A; Klesse S; Panagiota V; Stadler M; Wichmann M; Shahswar R; Platzbecker U; Thiede C; Schroeder T; Kobbe G; Geffers R; Schlegelberger B; Göhring G; Kreipe HH; Germing U; Ganser A; Kröger N; Koenecke C; Thol F
Ann Hematol; 2017 Aug; 96(8):1361-1372. PubMed ID: 28612220
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndrome: Experience of the Argentinean Group of Bone Marrow Transplantation (GATMO).
Basquiera AL; Rivas MM; Remaggi G; Klein G; Milovic V; Foncuberta MC; Saba S; Milone JH; Arbelbide J; Jaimovich G; Rolón JM; Kusminsky G; García JJ; Prates MV
Hematology; 2016 Apr; 21(3):162-9. PubMed ID: 26147089
[TBL] [Abstract][Full Text] [Related]
13. TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.
Kharfan-Dabaja MA; Komrokji RS; Zhang Q; Kumar A; Tsalatsanis A; Perkins J; Nishihori T; Field T; Al Ali N; Mishra A; Sallman D; Salem KZ; Zhang L; Moscinski L; Fernandez HF; Lancet J; List A; Anasetti C; Padron E
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):753-758. PubMed ID: 28687222
[TBL] [Abstract][Full Text] [Related]
14. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic hematopoietic stem cell transplantation in pediatric myelodysplastic syndromes: a multicenter experience from Argentina.
Basquiera AL; Pizzi S; Correas AG; Longo PG; Goldman WC; Prates MV; Formisano S; Kusminisky G; Feldman L; Berretta AR; García JJ; Staciuk R
Pediatr Blood Cancer; 2015 Jan; 62(1):153-7. PubMed ID: 25264233
[TBL] [Abstract][Full Text] [Related]
17. Positive impact of chronic graft-versus-host disease on the outcome of patients with de novo myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: a single-center analysis of 115 patients.
Hiramoto N; Kurosawa S; Tajima K; Okinaka K; Tada K; Kobayashi Y; Shinohara A; Inoue Y; Ueda R; Tanaka T; Kim SW; Yamashita T; Heike Y; Fukuda T
Eur J Haematol; 2014 Feb; 92(2):137-46. PubMed ID: 24127668
[TBL] [Abstract][Full Text] [Related]
18. TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Marvin-Peek J; Mason EF; Kishtagari A; Jayani RV; Dholaria B; Kim TK; Engelhardt BG; Chen H; Strickland S; Savani B; Ferrell B; Kassim A; Savona M; Mohan S; Byrne M
Transplant Cell Ther; 2023 Jun; 29(6):390.e1-390.e10. PubMed ID: 36906277
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes.
Sharma P; Shinde SS; Damlaj M; Hefazi Rorghabeh M; Hashmi SK; Litzow MR; Hogan WJ; Gangat N; Elliott MA; Al-Kali A; Tefferi A; Patnaik MM
Leuk Lymphoma; 2017 Apr; 58(4):872-881. PubMed ID: 27687869
[TBL] [Abstract][Full Text] [Related]
20. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.
Yoshizato T; Nannya Y; Atsuta Y; Shiozawa Y; Iijima-Yamashita Y; Yoshida K; Shiraishi Y; Suzuki H; Nagata Y; Sato Y; Kakiuchi N; Matsuo K; Onizuka M; Kataoka K; Chiba K; Tanaka H; Ueno H; Nakagawa MM; Przychodzen B; Haferlach C; Kern W; Aoki K; Itonaga H; Kanda Y; Sekeres MA; Maciejewski JP; Haferlach T; Miyazaki Y; Horibe K; Sanada M; Miyano S; Makishima H; Ogawa S
Blood; 2017 Apr; 129(17):2347-2358. PubMed ID: 28223278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
